Abstract:KRAS mutations have been established as a major predictive biomarker for resistance to the treatment of metastatic colorectal cancer (mCRC) with anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MoAbs). However, many patients with KRAS wild-type tumors still do not respond to the treatment. We conducted a systematic review with meta-analysis to assess whether BRAF mutations, PIK3CA mutations and PTEN loss can predict the outcomes of patients with KRAS wild-type mCRC treated with anti-EGFR MoAbs. Studies that explored the association of one or more of the three biomarkers with progression-free survival (PFS), overall survival (OS) and/or objective response rate (ORR) were identified through August 2012. Summary hazard ratios (HRs) and rate differences (RDs) and corresponding 95% confidence intervals (CIs) were calculated by using the random-effects model. BRAF mutations, PIK3CA exon 20 mutations and PTEN loss were all associated with shorter PFS (HR=2.59, 95% CI 1.67-4.03; HR=2.52, 95% CI 1.33-4.78 and HR=1.75, 95% CI 1.19-2.56, respectively), shorter OS (HR=2.74, 95% CI 1.79-4.19; HR=3.29, 95% CI 1.60-6.75 and HR=1.85, 95% CI 1.30-2.64, respectively) and lower ORR (RD=-36%, 95% CI -44 to -28%; RD=-38%, 95% CI -51 to -24% and RD=-41%, 95% CI -68 to -14%, respectively). PIK3CA exon 9 mutations were associated with none of the outcomes. Studies with relevant data consistently demonstrated a stronger predictive power of combined multiple biomarkers as compared to one alteration alone. These results suggest that BRAF mutations, PIK3CA exon 20 mutations and PTEN loss are predictive of better outcomes in KRAS wild-type mCRC treated with anti-EGFR MoAbs. However, the quality of included studies varied, and some of the meta-analyses were limited by significant between-study heterogeneity. In the future, well-designed large randomized controlled trials conducted in KRAS wild-type mCRC patients with subgroup analysis according to BRAF, PIK3CA exon 20 and PTEN status are essential to fully assess the clinical relevance of these biomarkers.What's new? Metastatic colorectal cancer (mCRC) is associated with a particularly poor prognosis. Monoclonal antibodies against EGFR are effective, but only for a small percentage of mCRC patients. KRAS mutations are a major predictive biomarker for resistance to anti-EGFR therapy; however, many patients with wild-type KRAS also fail to respond. In order to identify other potential biomarkers, the authors conducted a meta-analysis of previous studies, and found that BRAF mutation, PIK3CA exon 20 mutation, and PTEN loss were consistently associated with a poor response. These data may allow further selection of KRAS wild-type mCRC patients who may benefit from anti-EGFR treatment.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Promising Biomarkers for Predicting the Outcomes of Patients Withkraswild-Type Metastatic Colorectal Cancer Treated with Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies: A Systematic Review with Meta-Analysis

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

Promising Biomarkers For Predicting The Outcomes Of Patients With Kras Wild-Type Metastatic Colorectal Cancer Treated With Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies: A Systematic Review With Meta-Analysis (Vol 133, 1914-1925, 2013)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

EGFR and KRAS in Colorectal Cancer

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

KRAS Status and Resistance to Epidermal Growth Factor Receptor Tyrosine‐kinase Inhibitor Treatment in Patients with Metastatic Colorectal Cancer: a Meta‐analysis

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Effect of RAS Status on Anti-Egfr Monoclonal Antibodies + 5-FU Infusion-Based Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer: A Meta-Analysis

EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer

Effect of RAS on Anti-Egfr Monoclonal Antibodies Plus 5-FU Infusion-Based Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer: A Meta-Analysis.

Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer

Using next-generation sequencing technology to evaluate biomarkers associated with anti-EGFR efficacy in metastatic colorectal cancer

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment